65,437 trials
Multiple Sclerosis (MS)
Primary: Mean Overall Response Score (ORS) — -0.74; -0.75; -0.64 score on a scale
Skin Cancer
Primary: To Ascertain the Percentage of Surgical Site Infections Following Excision of Ulcerated Skin Tumours in Dermatology Departments. — 35 Participants
Attention Deficit Hyperactivity Disorder
Primary: Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score During the Double-Blind Treatment Period — 12.81; 18.67 score on a scale — p=< 0.001
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin
Primary: Response Rate of Cetuximab by RECIST Criteria — 15 Participants
Astigmatism
Primary: Subjective Handling Rating on Lens Removal — 85.5; 83.3 units on a scale
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Primary: Clinical Response to Crenolanib With Standard Salvage Chemotherapy — 7; 3; 4; 0 Participants
Childhood Solid Neoplasm · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: Maximum Tolerated Dose (MTD) of Prexasertib — 150 mg/m^2
Herpes Zoster
Primary: Anti-glycoprotein E (Anti-gE) Antibody Concentrations, as Assessed in the Long Term Follow-up (LTFU) Phase of the Current ZOSTER-073 Study — 3729.8; 3440.2; 3075.8 mIU/mL
Food Preferences · Obesity · Weight Gain
Primary: Number of Participants Purchasing Beverages With Calories — 1005; 765; 763; 748 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With BIO 300 Oral Suspension-related Dose Limiting Toxicity — 0; 0; 0; 6 Participants
Maternal Opioid Use Disorder · Opioid Exposed Infant
Primary: Fetal Heart Rate at 24 Weeks — 143.64 beats per minute
Atherosclerosis · Adherence, Medication · Tolerance
Primary: Carotid Intimal Media Thickness — -0.017; -0.092 mm
Visual Acuity
Primary: Proportion of Eyes With Acceptable Lens Fitting — 100; 100 Proportion of eyes
Scleroderma, Systemic · Scleroderma, Diffuse · Sclerosis, Systemic
Primary: FT011 Levels in Plasma — 5.45; 10.3 ug/mL
Acute Bacterial Skin and Skin Structure Infection
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 1; 0; 0 Participants